Defense Health Program Department of Defense Lung Cancer Research Program Funding Opportunities for Fiscal Year 2020 (FY20)

How to Apply: 

The FY20 Defense Appropriations Act provides funding to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).


The FY20 LCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the website.


Applications submitted to the FY20 LCRP must address one or more of the following Areas of Emphasis:

*Identify innovative strategies for the screening and early detection of lung cancer.

*Understand the molecular mechanisms of initiation and progression to lung cancer.

*Identify innovative strategies for prevention of the occurrence of lung cancer.

*Identify innovative strategies for the treatment of lung cancer.

*Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.

*Develop or optimize prognostic or predictive markers to assist with therapeutic decision-making.

*Understand mechanisms of resistance to treatment (primary and secondary).

*Understand contributors to lung cancer development other than tobacco.

*Identify innovative strategies for lung cancer care delivery (disparities/clinical management/ surveillance/symptom management).


Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the DHP and FY20 LCRP during programmatic review.   Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

*Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research

*Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators

*Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population

*Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco


Career Development Award – Letter of Intent due July 15, 2020

  • Independent investigators the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment.
  • Must not have received a Career Development Award previously from any program within the Congressionally Directed Medical Research Programs.
  • Must not have received more than $300,000 in total direct costs for previous or concurrent lung cancer research as a PI of one or more Federally or privately funded, non-mentored, peer-reviewed grants.
  • Mentor
  • At or above the level of Associate Professor (or equivalent).
  • Must have a strong publication and funding record in lung cancer research.
  • Supports early-career, independent researchers to conduct research under the mentorship of an experienced lung cancer researcher.
  • Clinical trials not allowed.
  • Preliminary data discouraged.
  • Military relevance strongly encouraged.
  • Maximum funding of $250,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 2 year.


Clinical Translational Research Partnership Award – Letter of Intent due July 15, 2020

Investigators at or above the level of Assistant Professor (or equivalent).

  • Supports translational studies that include a clinical trial.
  • Intended to fund partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications.
  • One partner is strongly encouraged to be from either a military treatment facility of a Department of Veterans Affairs medical center.
  • Non-traditional partnerships are encouraged.
  • Preliminary lung cancer relevant data required.
  • Military relevance strongly encouraged.
  • Patient research advocate involvement encouraged.
  • Maximum combined funding of $1,200,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 3 years.


A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the website.  The application package containing the required forms for each award mechanism will also be found on  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420. 


For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website.

Point of Contact:


CDMRP Help Desk



External Deadline: 
Wednesday, July 15, 2020
Funding Source: 
Funding Level: